CalciMedica Stock (NASDAQ:CALC)


ForecastFinancialsChart

Previous Close

$2.76

52W Range

$2.05 - $8.38

50D Avg

$3.44

200D Avg

$4.32

Market Cap

$38.29M

Avg Vol (3M)

$59.27K

Beta

-

Div Yield

-

CALC Company Profile


CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

13

IPO Date

Jun 14, 2023

Website

CALC Performance


CALC Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income-$-36.18M$-35.95M
Net Income-$-35.60M$-35.82M
EBITDA-$-29.92M$-35.95M
Basic EPS-$-23.20$-23.66
Diluted EPS-$-23.20$-23.66

Fiscal year ends in Dec 23 | Currency in USD